Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

Shareholders in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) had a terrible week, as shares crashed 27% to US$4.16 in the week since its latest first-quarter results. It wasn't the greatest ...

Recursion Pharmaceuticals has an innovative, AI-focused approach to developing drugs. However, the company has yet to find tangible success and faces several headwinds. The stock has substantial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Most of the time, we’re talking about a family of fluid-visualization techniques. We owe that nomenclature to German physicist August Toepler, who applied these optical techniques to visualizing ...

Artificial Intelligence (AI) is reshaping the field of data visualization, making it faster, smarter, and more accessible than ever before. “AI is not just about fancier dashboards. Think about ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The latest price target for Recursion Pharmaceuticals (NASDAQ:RXRX) was reported by Needham on May 6, 2025. The analyst firm set a price target for $8.00 expecting RXRX to rise to within 12 months ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry ...

Long-term support release due in September has grown to 17 features including ahead-of-time command-line ergonomics and ahead-of-time method profiling. Java Development Kit (JDK) 25, a planned ...